Clinical trial results:
A Multicenter, International, Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Efficacy, Safety, and Tolerability of Daily Oral Dosing of Tafamidis Meglumine (PF-06291826) 20 mg or 80 mg in Comparison to Placebo in Subjects Diagnosed With Transthyretin Cardiomyopathy (TTR-CM)

Summary

EudraCT number	2012-002465-35
Trial protocol	GB IT ES DE SE CZ NL BE
Global end of trial date	07 February 2018

Results information

Result version number	v2 (current)
This version publication date	01 May 2019
First version publication date	16 February 2019
Version creation reason	

Trial information

Trial identification

Sponsor protocol code	B3461028

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01994889
WHO universal trial number (UTN)	-
Other trial identifiers	ATTR-ACT: Other Identifier: Alias Study Number

Notes:

Sponsors

Sponsor organisation name	Pfizer Inc.
Sponsor organisation address	235 E 42nd Street, New York, United States, NY 10017
Public contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 18007181021, ClinicalTrials.gov_Inquiries@pfizer.com
Scientific contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 18007181021, ClinicalTrials.gov_Inquiries@pfizer.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	28 August 2018
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	07 February 2018
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To assess the efficacy of an oral dose of 20 milligrams (mg) or 80 mg tafamidis meglumine soft-gel capsules based on all-cause mortality and on frequency of cardiovascular-related hospitalizations as well as to assess safety and tolerability in comparison to placebo.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Council for Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	09 December 2013
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Belgium: 2
Country: Number of subjects enrolled	Brazil: 2
Country: Number of subjects enrolled	Canada: 1
Country: Number of subjects enrolled	Czech Republic: 8
Country: Number of subjects enrolled	France: 28
Country: Number of subjects enrolled	Germany: 49
Country: Number of subjects enrolled	Italy: 29
Country: Number of subjects enrolled	Japan: 17
Country: Number of subjects enrolled	Netherlands: 7
Country: Number of subjects enrolled	Spain: 9
Country: Number of subjects enrolled	Sweden: 6
Country: Number of subjects enrolled	United Kingdom: 4
Country: Number of subjects enrolled	United States: 279
Worldwide total number of subjects	441
EEA total number of subjects	142

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	42
From 65 to 84 years	377
85 years and over	22

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

Pooled analysis of the tafamidis treatment groups 20 mg and 80 mg was performed in comparison to placebo group.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	Tafamidis 20 mg

Arm description:

Subjects with variant transthyretin cardiomyopathy (TTR-CM) genotype or wild-type TTRCM genotype received one tafamidis 20 milligram (mg) capsule + 3 placebo capsules (matched to tafamidis) orally once daily for 30 months.

Arm type	Experimental
Investigational medicinal product name	Tafamidis meglumine
Investigational medicinal product code	PF-06291826
Other name	
Pharmaceutical forms	Capsule, soft
Routes of administration	Oral use

Dosage and administration details:

One tafamidis 20 mg capsule + 3 placebo capsules (matched to tafamidis), orally once daily for 30 months.

Arm title	Tafamidis 80 mg

Arm description:

Subjects with variant TTR-CM genotype or wild-type TTR-CM genotype received tafamidis 80 mg (4 capsules of 20 mg each) orally once daily for 30 months.

Arm type	Experimental
Investigational medicinal product name	Tafamidis meglumine
Investigational medicinal product code	PF-06291826
Other name	
Pharmaceutical forms	Capsule, soft
Routes of administration	Oral use

Dosage and administration details:

Tafamidis 80 mg (4 capsules of 20 mg each), orally once daily for 30 months.

Arm title	Placebo

Arm description:

Subjects with variant TTR-CM genotype or wild-type TTR-CM genotype received 4 placebo capsules matched to tafamidis orally once daily for 30 months.

Arm type	Placebo

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule, soft
Routes of administration	Oral use

Dosage and administration details:

Four placebo capsules (matched to tafamidis), orally once daily for 30 months.

Number of subjects in period 1	Tafamidis 20 mg	Tafamidis 80 mg	Placebo
Started	88	176	177
Completed	60	113	85
Not completed	28	63	92
Adverse event, serious fatal	5	8	7
Organ Transplantation	1	5	5
Adverse event, non-fatal	-	1	1
Death	14	25	38
Adverse event, serious non fatal	-	3	3
No longer willing to participate	8	17	37
Cardiac Device Implantation	-	2	-
Lost to follow-up	-	1	-
Protocol deviation	-	1	1

Baseline characteristics

Reporting groups	
Reporting group title	Tafamidis 20 mg
Reporting group description:	
Subjects with variant transthyretin cardiomyopathy (TTR-CM) genotype or wild-type TTRCM genotype received one tafamidis 20 milligram (mg) capsule + 3 placebo capsules (matched to tafamidis) orally once daily for 30 months.	
Reporting group title	Tafamidis 80 mg
Reporting group description:	
Subjects with variant TTR-CM genotype or wild-type TTR-CM genotype received tafamidis 80 mg (4 capsules of 20 mg each) orally once daily for 30 months.	
Reporting group title	Placebo
Reporting group description:	
Subjects with variant TTR-CM genotype or wild-type TTR-CM genotype received 4 placebo capsules matched to tafamidis orally once daily for 30 months.	

Reporting group values	Tafamidis 20 mg	Tafamidis 80 mg	Placebo
Number of subjects	88	176	177
Age categorical			
The intent-to-treat (ITT) analysis set included all subjects in the safety population (all randomized subjects who received at least 1 dose of double-blind medication) who had at least 1 post baseline efficacy evaluation (post baseline hospitalization, study visit, or date of death).			
Units: Subjects			
Adults (18-64 years)	11	16	15
From 65-84 years	74	148	155
85 years and over	3	12	7
Age Continuous			
The ITT analysis set included all subjects in the safety population (all randomized subjects who received at least 1 dose of double-blind medication) who had at least 1 post baseline efficacy evaluation (post baseline hospitalization, study visit, or date of death).			
Units: years			
arithmetic mean	73.3	75.2	74.1
standard deviation	± 7.07	± 7.24	± 6.69
Sex: Female, Male			
The ITT analysis set included all subjects in the safety population (all randomized subjects who received at least 1 dose of double-blind medication) who had at least 1 post baseline efficacy evaluation (post baseline hospitalization, study visit, or date of death).			
Units: Subjects			
Female	5	18	20
Male	83	158	157
Race (NIH/OMB)			
The ITT analysis set included all subjects in the safety population (all randomized subjects who received at least 1 dose of double-blind medication) who had at least 1 post baseline efficacy evaluation (post baseline hospitalization, study visit, or date of death).			
Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	2	11	5
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	11	26	26
White	75	136	146
More than one race	0	0	0

Unknown or Not Reported	0	3	0
Ethnicity (NIH/OMB)			
The ITT analysis set included all subjects in the safety population (all randomized subjects who received at least 1 dose of double-blind medication) who had at least 1 post baseline efficacy evaluation (post baseline hospitalization, study visit, or date of death).			
Units: Subjects			
Hispanic or Latino	3	4	7
Not Hispanic or Latino	84	171	170
Unknown or Not Reported	1	1	0

Reporting group values	Total		
Number of subjects	441		
Age categorical			
The intent-to-treat (ITT) analysis set included all subjects in the safety population (all randomized subjects who received at least 1 dose of double-blind medication) who had at least 1 post baseline efficacy evaluation (post baseline hospitalization, study visit, or date of death).			
Units: Subjects			
Adults (18-64 years)	42		
From 65-84 years	377		
85 years and over	22		
Age Continuous			
The ITT analysis set included all subjects in the safety population (all randomized subjects who received at least 1 dose of double-blind medication) who had at least 1 post baseline efficacy evaluation (post baseline hospitalization, study visit, or date of death).			
Units: years			
arithmetic mean			
standard deviation	-		
Sex: Female, Male			
The ITT analysis set included all subjects in the safety population (all randomized subjects who received at least 1 dose of double-blind medication) who had at least 1 post baseline efficacy evaluation (post baseline hospitalization, study visit, or date of death).			
Units: Subjects			
Female	43		
Male	398		
Race (NIH/OMB)			
The ITT analysis set included all subjects in the safety population (all randomized subjects who received at least 1 dose of double-blind medication) who had at least 1 post baseline efficacy evaluation (post baseline hospitalization, study visit, or date of death).			
Units: Subjects			
American Indian or Alaska Native	0		
Asian	18		
Native Hawaiian or Other Pacific Islander	0		
Black or African American	63		
White	357		
More than one race	0		
Unknown or Not Reported	3		
Ethnicity (NIH/OMB)			
The ITT analysis set included all subjects in the safety population (all randomized subjects who received at least 1 dose of double-blind medication) who had at least 1 post baseline efficacy evaluation (post baseline hospitalization, study visit, or date of death).			
Units: Subjects			
Hispanic or Latino	14		
Not Hispanic or Latino	425		
Unknown or Not Reported	2		

End points

End points reporting groups

Reporting group title	Tafamidis 20 mg

Reporting group description:

Subjects with variant transthyretin cardiomyopathy (TTR-CM) genotype or wild-type TTRCM genotype received one tafamidis 20 milligram (mg) capsule + 3 placebo capsules (matched to tafamidis) orally once daily for 30 months.

Reporting group title	Tafamidis 80 mg

Reporting group description:

Subjects with variant TTR-CM genotype or wild-type TTR-CM genotype received tafamidis 80 mg (4 capsules of 20 mg each) orally once daily for 30 months.

Reporting group title	Placebo

Reporting group description:

Subjects with variant TTR-CM genotype or wild-type TTR-CM genotype received 4 placebo capsules matched to tafamidis orally once daily for 30 months.

Subject analysis set title	Tafamidis
Subject analysis set type	Intention-to-treat

Subject analysis set description:

Subjects with variant TTR-CM genotype or wild-type TTR-CM genotype received one tafamidis 20 mg + 3 placebo capsules (matched to tafamidis) or 80 mg (4 capsules of 20 mg each) capsule orally once daily for 30 months.

Primary: Hierarchical Combination of All-Cause Mortality and Frequency of Cardiovascular (CV)-Related Hospitalizations

End point title	Hierarchical Combination of All-Cause Mortality and Frequency of Cardiovascular (CV)-Related Hospitalizations[1]

End point description:

All-cause mortality and frequency of CV hospitalization were analyzed using Finkelstein-Schoenfeld method, which combines in a hierarchical fashion using all-cause mortality first. The method compares every subject with every other subject within strata, assigning a +1 to the “better” subject and a -1 to the “worse” subject and 0 if they are “tied”. Subjects who discontinued for transplantation (heart transplantation and combined heart and liver transplantation) or for implantation of a cardiac mechanical assist device, were handled in the same manner as death. 'Win' represents a subject doing better based on hierarchical comparison. The reported unit is the total ‘wins’ for each treatment group from performing such a hierarchical comparison across all 4 strata in the study. Analysis done on ITT analysis set. Pre-specified intent of study was to compare results between tafamidis with placebo,irrespective of tafamidis doses. Analysis based on pooled dose groups,as per study protocol.

End point type	Primary

End point timeframe:

Baseline up to Month 30

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: All patients receiving active medication (Tafamidis 20mg and Tafamidis 80 mg) are included in the pooled analysis

End point values	Placebo	Tafamidis		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	177	264		
Units: wins				
number (not applicable)	5071	8595		

Statistical analyses

Statistical analysis title	Tafamidis Vs. Placebo
Comparison groups	Placebo v Tafamidis
Number of subjects included in analysis	441
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0006
Method	Finkelstein-Schoenfeld Method

Secondary: All-Cause Mortality

End point title	All-Cause Mortality[2]

End point description:

Number of deaths during the study due to any cause was analyzed. Subjects who discontinued for transplantation (heart transplantation and combined heart and liver transplantation) or for implantation of a cardiac mechanical assist device were handled in the same manner as death. The ITT analysis set included all subjects in the safety population (all randomized subjects who received at least 1 dose of double-blind medication) who had at least 1 post baseline efficacy evaluation (post baseline hospitalization, study visit, or date of death). The pre-specified intent of this study was to compare the results between tafamidis with placebo, irrespective of the tafamidis doses. Therefore, this analysis was based on the pooled dose groups, as per the study protocol.

End point type	Secondary

End point timeframe:

Baseline up to Month 30

Notes:

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: All patients receiving active medication (Tafamidis 20mg and Tafamidis 80 mg) are included in the pooled analysis

End point values	Placebo	Tafamidis		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	177	264		
Units: subjects				
Deaths (all causes)	72	69		
Heart transplants	4	7		
Cardiac Mechanical Assist Devices	0	2		

Statistical analyses

Statistical analysis title	Tafamidis Vs. Placebo

Statistical analysis description:

Hazard ratio from a Cox proportional hazards model with treatment, TTR genotype (variant and wild-type) and New York Heart Association (NYHA) baseline classification (NYHA Classes I and II combined and NYHA Class III) in the model.

Comparison groups	Placebo v Tafamidis

Number of subjects included in analysis	441
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0259
Method	Cox proportional hazards model
Parameter estimate	Hazard ratio (HR)
Point estimate	0.698
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.508
upper limit	0.958

Secondary: Frequency of Cardiovascular-Related Hospitalizations

End point title	Frequency of Cardiovascular-Related Hospitalizations[3]

End point description:

CV related hospitalizations per year is calculated as subject's number of CV related hospitalizations upon duration on study in years. The ITT analysis set included all subjects in the safety population (all randomized subjects who received at least 1 dose of double-blind medication) who had at least 1 post baseline efficacy evaluation (post baseline hospitalization, study visit, or date of death). The pre-specified intent of this study was to compare the results between tafamidis with placebo, irrespective of the tafamidis doses. Therefore, this analysis was based on the pooled dose groups, as per the study protocol.

End point type	Secondary

End point timeframe:

Baseline to Month 30

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: All patients receiving active medication (Tafamidis 20mg and Tafamidis 80 mg) are included in the pooled analysis

End point values	Placebo	Tafamidis		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	177	264		
Units: CV hospitalization per year				
arithmetic mean (standard deviation)	0.884 (± 1.2032)	0.999 (± 2.2777)		

Statistical analyses

Statistical analysis title	Tafamidis Vs. Placebo
Comparison groups	Placebo v Tafamidis

Number of subjects included in analysis	441
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [4]
Method	Poisson regression analysis
Parameter estimate	Risk ratio (RR)
Point estimate	0.6761
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.5639
upper limit	0.8107

Notes:

[4] - Poisson regression analysis with treatment, TTR Genotype, NYHA Baseline classification, treatment-by-TTR genotype interaction, and treatment-by-NYHA Baseline classification interaction terms as factors adjusted for treatment duration.

Secondary: Change From Baseline in the Total Distance Walked During 6 Minute Walk Test (6MWT) at Month 30

End point title	Change From Baseline in the Total Distance Walked During 6 Minute Walk Test (6MWT) at Month 30[5]

End point description:

6MWT is the total distance that a subject could walk in 6 minutes. Subjects were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed. The ITT analysis set included all subjects in the safety population (all randomized subjects who received at least 1 dose of double-blind medication) who had at least 1 post baseline efficacy evaluation (post baseline hospitalization, study visit, or date of death). The pre-specified intent of this study was to compare the results between tafamidis with placebo, irrespective of the tafamidis doses. Therefore, this analysis was based on the pooled dose groups, as per the study protocol. Here, 'n' = Subjects evaluable for this end point at specified time points.

End point type	Secondary

End point timeframe:

Baseline, Month 30

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: All patients receiving active medication (Tafamidis 20mg and Tafamidis 80 mg) are included in the pooled analysis

End point values	Placebo	Tafamidis		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	177	264		
Units: meters				
arithmetic mean (standard deviation)				
Baseline (n=177, 264)	353.26 (± 125.983)	350.55 (± 121.296)		
Change at Month 30 (n=70, 155)	-89.67 (± 105.159)	-30.46 (± 87.886)		

Statistical analyses

Statistical analysis title	Tafamidis Vs. Placebo

Statistical analysis description:

L.S. means are from an ANCOVA (MMRM) model with an unstructured covariance matrix; center and

subject within center as random effects; treatment, visit, TTR genotype (variant and wild-type), and visit by treatment interaction, as fixed effects and baseline score as covariate.

Comparison groups	Placebo v Tafamidis
Number of subjects included in analysis	441
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed Model Repeated Measures ANCOVA
Parameter estimate	Least Square Mean Difference
Point estimate	75.68
Confidence interval	
level	95 %
sides	2-sided
lower limit	57.56
upper limit	93.8
Variability estimate	Standard error of the mean
Dispersion value	9.236

Secondary: Change from Baseline in Kansas City Cardiomyopathy Questionnaire Overall Score (KCCQ-OS) at Month 30

End point title	Change from Baseline in Kansas City Cardiomyopathy Questionnaire Overall Score (KCCQ-OS) at Month 30[6]

End point description:

KCCQ: 23-item subject-completed questionnaire that assesses health status and health-related quality of life in subjects with heart failure. Eight domain scores were calculated: Physical limitation, Social limitation, Quality of life, Self-efficacy, Symptom stability, Symptom frequency, Symptom burden, and Total symptoms (calculated as the mean of Symptom frequency and Symptom burden scores). Two summary scores were calculated: Clinical Summary (calculated as mean of Physical limitation and Total symptom scores) and Overall Summary (calculated as mean of Physical limitation, Social limitation, Total symptoms, and Quality of life scores). Domain and summary scores ranged from 0 (minimum) to 100 (maximum); higher scores represent better health status. Analysis done on ITT analysis set. Pre-specified intent of study was to compare results between tafamidis with placebo,irrespective of tafamidis doses. Here, 'n' = Subjects evaluable for this end point at specified categories.

End point type	Secondary

End point timeframe:

Baseline, Month 30

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: All patients receiving active medication (Tafamidis 20mg and Tafamidis 80 mg) are included in the pooled analysis

End point values	Placebo	Tafamidis		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	177	264		
Units: units on a scale				
arithmetic mean (standard deviation)				
Baseline (n=177, 264)	65.898 (± 21.7357)	67.274 (± 21.3561)		
Change at Month 30 (n=84,170)	-14.637 (± 21.4078)	-3.855 (± 19.3075)		

Statistical analyses

Statistical analysis title	Tafamidis Vs. Placebo
Statistical analysis description: Change at Month 30: Overall Summary	
Comparison groups	Placebo v Tafamidis
Number of subjects included in analysis	441
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed Model Repeated Measures ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	13.65
Confidence interval	
level	95 %
sides	2-sided
lower limit	9.48
upper limit	17.83
Variability estimate	Standard error of the mean
Dispersion value	2.13

Secondary: Number of Subjects With Cardiovascular-Related Mortality

End point title	Number of Subjects With Cardiovascular-Related Mortality[7]

End point description:

Deaths adjudicated as CV-related and indeterminate are reported. Subjects who discontinued for transplantation (heart transplantation and combined heart and liver transplantation) or for implantation of a cardiac mechanical assist device, were handled in the same manner as death. The ITT analysis set included all subjects in the safety population (all randomized subjects who received at least 1 dose of double-blind medication) who had at least 1 post baseline efficacy evaluation (post baseline hospitalization, study visit, or date of death). The pre-specified intent of this study was to compare the results between tafamidis with placebo, irrespective of the tafamidis doses. Therefore, this analysis was based on the pooled dose groups, as per the study protocol.

End point type	Secondary

End point timeframe:

Baseline up to Month 30

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: All patients receiving active medication (Tafamidis 20mg and Tafamidis 80 mg) are included in the pooled analysis

End point values	Placebo	Tafamidis		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	177	264		
Units: subjects	63	64		

Statistical analyses

Statistical analysis title	Tafamidis Vs.Placebo

Statistical analysis description:

Hazard ratio from a Cox proportional hazards model with treatment, TTR genotype (variant and wild-type) and NYHA baseline classification (NYHA Classes I and II combined and NYHA Class III) in the model.

Comparison groups	Placebo v Tafamidis
Number of subjects included in analysis	441
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0383
Method	Cox proportional hazards model
Parameter estimate	Hazard ratio (HR)
Point estimate	0.691
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.488
upper limit	0.98

Secondary: Percentage of Subjects With Stabilized Transthyretin (TTR) at Month 1

End point title	Percentage of Subjects With Stabilized Transthyretin (TTR) at Month 1[8]

End point description:

TTR stabilization is a measure of the degree of stabilization afforded the TTR molecule by tafamidis. The ITT analysis set included all subjects in the safety population (all randomized subjects who received at least 1 dose of double-blind medication) who had at least 1 post baseline efficacy evaluation (post baseline hospitalization, study visit, or date of death). The pre-specified intent of this study was to compare the results between tafamidis with placebo, irrespective of the tafamidis doses. Therefore, this analysis was based on the pooled dose groups, as per the study protocol. Here, 'Number analyzed' = Subjects evaluable for this end point.

End point type	Secondary

End point timeframe:

Month 1

Notes:

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: All patients receiving active medication (Tafamidis 20mg and Tafamidis 80 mg) are included in the pooled analysis

End point values	Placebo	Tafamidis		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	170	245		
Units: percentage of subjects				
number (not applicable)	3.5	86.1		

Statistical analyses

Statistical analysis title	Tafamidis Vs.Placebo
Comparison groups	Placebo v Tafamidis
Number of subjects included in analysis	415
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Chi-squared

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Baseline up to 28 days after last dose of study drug (Month 31)

Adverse event reporting additional description:

Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one subject and as non-serious in another, or a subject may have experienced both a serious and non-serious event. Analysis performed on safety population.

Assessment type	Non-systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	20.1

Reporting groups

Reporting group title	Tafamidis 20 mg

Reporting group description:

Participants with variant transthyretin cardiomyopathy (TTR-CM) genotype or wild-type TTRCM genotype received one tafamidis 20 milligram (mg) capsule orally once daily for 30 months.

Reporting group title	Tafamidis 80 mg

Reporting group description:

Participants with variant TTR-CM genotype or wild-type TTR-CM genotype received tafamidis 80 mg (4 capsules of 20 mg each) orally once daily for 30 months.

Reporting group title	Placebo

Reporting group description:

Participants with variant TTR-CM genotype or wild-type TTR-CM genotype received 4 placebo capsules matched to tafamidis orally once daily for 30 months.

Serious adverse events	Tafamidis 20 mg	Tafamidis 80 mg	Placebo
Total subjects affected by serious adverse events			
subjects affected / exposed	66 / 88 (75.00%)	133 / 176 (75.57%)	140 / 177 (79.10%)
number of deaths (all causes)	23	49	72
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Basal cell carcinoma			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bladder cancer			

subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bladder transitional cell carcinoma			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breast cancer			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gallbladder adenocarcinoma			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intraductal papilloma of breast			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung neoplasm malignant			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant melanoma			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastatic squamous cell carcinoma			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Oesophageal adenocarcinoma			

subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Prostate cancer			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal adenoma			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal neoplasm			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Testicular neoplasm			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transitional cell carcinoma metastatic			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Aortic dissection			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Circulatory collapse			

subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Deep vein thrombosis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematoma			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	2 / 177 (1.13%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphoedema			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Orthostatic hypotension			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	2 / 177 (1.13%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral vascular disorder			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	2 / 177 (1.13%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Shock haemorrhagic			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
General disorders and administration site conditions			
Asthenia			

subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest discomfort			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	2 / 88 (2.27%)	4 / 176 (2.27%)	2 / 177 (1.13%)
occurrences causally related to treatment / all	0 / 3	0 / 5	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Disease progression			
subjects affected / exposed	1 / 88 (1.14%)	4 / 176 (2.27%)	3 / 177 (1.69%)
occurrences causally related to treatment / all	0 / 1	0 / 4	0 / 3
deaths causally related to treatment / all	0 / 3	0 / 11	0 / 9
General physical health deterioration			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	2 / 177 (1.13%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Generalised oedema			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incarcerated hernia			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Medical device site haematoma			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema peripheral			

subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral swelling			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	2 / 177 (1.13%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 88 (0.00%)	4 / 176 (2.27%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 5	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sudden cardiac death			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Sudden death			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death			
subjects affected / exposed	9 / 88 (10.23%)	24 / 176 (13.64%)	34 / 177 (19.21%)
occurrences causally related to treatment / all	0 / 9	0 / 24	0 / 34
deaths causally related to treatment / all	0 / 9	0 / 24	0 / 34
Immune system disorders			
Amyloidosis			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	2 / 177 (1.13%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 2
Reproductive system and breast disorders			
Benign prostatic hyperplasia			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Cervical dysplasia			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spermatocele			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute pulmonary oedema			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute respiratory failure			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	4 / 177 (2.26%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Asthma			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Choking			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cough			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Dyspnoea			
subjects affected / exposed	2 / 88 (2.27%)	3 / 176 (1.70%)	4 / 177 (2.26%)
occurrences causally related to treatment / all	0 / 2	0 / 3	1 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea exertional			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	2 / 177 (1.13%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epistaxis			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemoptysis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemothorax			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hiccups			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	2 / 177 (1.13%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Interstitial lung disease			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung disorder			

subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	5 / 88 (5.68%)	6 / 176 (3.41%)	4 / 177 (2.26%)
occurrences causally related to treatment / all	0 / 5	0 / 8	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia aspiration			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 88 (0.00%)	3 / 176 (1.70%)	2 / 177 (1.13%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary mass			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary oedema			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary toxicity			

subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory acidosis			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory distress			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Psychiatric disorders			
Completed suicide			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Confusional state			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Delirium			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mental status changes			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	4 / 177 (2.26%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Stress			

subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Product issues			
Device connection issue			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device dislocation			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device malfunction			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Anticoagulation drug level above therapeutic			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anticoagulation drug level below therapeutic			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood potassium decreased			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood sodium decreased			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Ejection fraction decreased			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
International normalised ratio increased			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Liver function test increased			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Streptococcus test positive			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transaminases increased			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Concussion			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Craniocerebral injury			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Facial bones fracture			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Fall			
subjects affected / exposed	5 / 88 (5.68%)	9 / 176 (5.11%)	5 / 177 (2.82%)
occurrences causally related to treatment / all	0 / 5	0 / 11	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Femoral neck fracture			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femur fracture			
subjects affected / exposed	1 / 88 (1.14%)	2 / 176 (1.14%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Forearm fracture			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Head injury			
subjects affected / exposed	0 / 88 (0.00%)	3 / 176 (1.70%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hip fracture			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint injury			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laceration			

subjects affected / exposed	2 / 88 (2.27%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Limb injury			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lumbar vertebral fracture			
subjects affected / exposed	2 / 88 (2.27%)	2 / 176 (1.14%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle rupture			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle strain			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal foreign body			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Overdose			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Procedural hypotension			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Procedural pain			

subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rib fracture			
subjects affected / exposed	0 / 88 (0.00%)	3 / 176 (1.70%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Road traffic accident			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Skin abrasion			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal compression fracture			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subarachnoid haemorrhage			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haematoma			
subjects affected / exposed	0 / 88 (0.00%)	3 / 176 (1.70%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Tendon rupture			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tibia fracture			

subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vasoplegia syndrome			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound dehiscence			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wrist fracture			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Familial amyloidosis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute left ventricular failure			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	3 / 177 (1.69%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Angina pectoris			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina unstable			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic valve stenosis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arrhythmia			
subjects affected / exposed	2 / 88 (2.27%)	2 / 176 (1.14%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arrhythmia supraventricular			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	7 / 88 (7.95%)	11 / 176 (6.25%)	8 / 177 (4.52%)
occurrences causally related to treatment / all	0 / 8	0 / 12	0 / 19
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial flutter			
subjects affected / exposed	2 / 88 (2.27%)	4 / 176 (2.27%)	5 / 177 (2.82%)
occurrences causally related to treatment / all	0 / 2	0 / 5	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial tachycardia			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial thrombosis			

subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrioventricular block			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrioventricular block complete			
subjects affected / exposed	1 / 88 (1.14%)	4 / 176 (2.27%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 1	0 / 4	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrioventricular block second degree			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bradycardia			
subjects affected / exposed	1 / 88 (1.14%)	5 / 176 (2.84%)	5 / 177 (2.82%)
occurrences causally related to treatment / all	0 / 1	0 / 5	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac amyloidosis			
subjects affected / exposed	2 / 88 (2.27%)	3 / 176 (1.70%)	5 / 177 (2.82%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 4	0 / 3
Cardiac arrest			
subjects affected / exposed	1 / 88 (1.14%)	2 / 176 (1.14%)	6 / 177 (3.39%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 6
deaths causally related to treatment / all	0 / 1	0 / 2	0 / 6
Cardiac failure			
subjects affected / exposed	16 / 88 (18.18%)	34 / 176 (19.32%)	39 / 177 (22.03%)
occurrences causally related to treatment / all	0 / 25	0 / 50	0 / 61
deaths causally related to treatment / all	0 / 4	0 / 6	0 / 6
Cardiac failure acute			

subjects affected / exposed	4 / 88 (4.55%)	23 / 176 (13.07%)	17 / 177 (9.60%)
occurrences causally related to treatment / all	0 / 5	0 / 30	0 / 28
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 2
Cardiac failure chronic			
subjects affected / exposed	1 / 88 (1.14%)	2 / 176 (1.14%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 1	0 / 5	0 / 6
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Cardiac failure congestive			
subjects affected / exposed	15 / 88 (17.05%)	20 / 176 (11.36%)	32 / 177 (18.08%)
occurrences causally related to treatment / all	0 / 17	0 / 31	0 / 46
deaths causally related to treatment / all	0 / 2	0 / 3	0 / 3
Cardio-respiratory arrest			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Cardiogenic shock			
subjects affected / exposed	3 / 88 (3.41%)	2 / 176 (1.14%)	4 / 177 (2.26%)
occurrences causally related to treatment / all	0 / 3	0 / 2	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Cardiomyopathy			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Cardiorenal syndrome			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic left ventricular failure			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Conduction disorder			

subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery disease			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	2 / 177 (1.13%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Left ventricular failure			
subjects affected / exposed	1 / 88 (1.14%)	3 / 176 (1.70%)	6 / 177 (3.39%)
occurrences causally related to treatment / all	0 / 1	0 / 4	0 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial depression			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nodal rhythm			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericardial effusion			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Right ventricular failure			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinus bradycardia			

subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Supraventricular tachycardia			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	2 / 177 (1.13%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Systolic dysfunction			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tachyarrhythmia			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tachycardia			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular arrhythmia			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular extrasystoles			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular fibrillation			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	3 / 177 (1.69%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Ventricular tachycardia			

subjects affected / exposed	2 / 88 (2.27%)	2 / 176 (1.14%)	7 / 177 (3.95%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 8
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Altered state of consciousness			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	2 / 177 (1.13%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ataxia			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Carpal tunnel syndrome			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral haemorrhage			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral infarction			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	1 / 88 (1.14%)	2 / 176 (1.14%)	4 / 177 (2.26%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cervicobrachial syndrome			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dizziness			

subjects affected / exposed	2 / 88 (2.27%)	0 / 176 (0.00%)	5 / 177 (2.82%)
occurrences causally related to treatment / all	0 / 2	0 / 0	1 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysarthria			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embolic cerebral infarction			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embolic stroke			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epilepsy			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage intracranial			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Hepatic encephalopathy			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lethargy			

subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Loss of consciousness			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Memory impairment			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolic encephalopathy			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuropathy peripheral			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Presyncope			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Somnolence			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			

subjects affected / exposed	0 / 88 (0.00%)	6 / 176 (3.41%)	10 / 177 (5.65%)
occurrences causally related to treatment / all	0 / 0	0 / 7	0 / 11
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			
subjects affected / exposed	3 / 88 (3.41%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uraemic encephalopathy			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coagulopathy			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukocytosis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Microcytic anaemia			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutrophilia			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			

Cataract			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Conjunctival haemorrhage			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	3 / 88 (3.41%)	1 / 176 (0.57%)	3 / 177 (1.69%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Abdominal pain upper			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ascites			
subjects affected / exposed	3 / 88 (3.41%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulum			

subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenitis			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric haemorrhage			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	2 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis haemorrhagic			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroduodenal ulcer			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorder			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	1 / 88 (1.14%)	2 / 176 (1.14%)	3 / 177 (1.69%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematemesis			

subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematochezia			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Impaired gastric emptying			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Melaena			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstructive pancreatitis			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophagitis			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			

subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tongue disorder			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cardiac cirrhosis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis acute			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholelithiasis			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic hepatitis			

subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Dermatitis contact			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erythema			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuropathic ulcer			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin ulcer			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stevens-Johnson syndrome			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Urticaria			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	9 / 88 (10.23%)	13 / 176 (7.39%)	15 / 177 (8.47%)
occurrences causally related to treatment / all	1 / 10	0 / 14	0 / 22
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Azotaemia			

subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Calculus urinary			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
End stage renal disease			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	1 / 88 (1.14%)	2 / 176 (1.14%)	4 / 177 (2.26%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydronephrosis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	1 / 88 (1.14%)	2 / 176 (1.14%)	3 / 177 (1.69%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Renal impairment			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal injury			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary bladder haemorrhage			

subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary retention			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back pain			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gouty arthritis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemarthrosis			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint swelling			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscular weakness			

subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neck pain			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteitis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	4 / 177 (2.26%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spondylolisthesis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Systemic lupus erythematosus			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Acute sinusitis			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis bacterial			

subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis infective			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacteraemia			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacterial sepsis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	2 / 88 (2.27%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	3 / 88 (3.41%)	2 / 176 (1.14%)	2 / 177 (1.13%)
occurrences causally related to treatment / all	0 / 4	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile colitis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Cystitis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			

subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocarditis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erysipelas			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infected skin ulcer			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infectious pleural effusion			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Influenza			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	2 / 177 (1.13%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			

subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Necrotising soft tissue infection			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ophthalmic herpes zoster			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteomyelitis			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Parainfluenzae virus infection			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	6 / 88 (6.82%)	13 / 176 (7.39%)	12 / 177 (6.78%)
occurrences causally related to treatment / all	0 / 6	0 / 14	0 / 13
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Pneumonia legionella			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia pneumococcal			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Pyelonephritis			

subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	2 / 177 (1.13%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhinitis			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	3 / 88 (3.41%)	1 / 176 (0.57%)	2 / 177 (1.13%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 1
Septic arthritis staphylococcal			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 1
Serratia infection			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinusitis			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal bacteraemia			

subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal infection			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Staphylococcal sepsis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subcutaneous abscess			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsillitis			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tracheobronchitis			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	2 / 88 (2.27%)	1 / 176 (0.57%)	5 / 177 (2.82%)
occurrences causally related to treatment / all	0 / 3	1 / 1	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral upper respiratory tract infection			

subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Cachexia			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	6 / 177 (3.39%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetes mellitus			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Electrolyte imbalance			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Failure to thrive			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fluid overload			
subjects affected / exposed	2 / 88 (2.27%)	2 / 176 (1.14%)	6 / 177 (3.39%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 12
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Fluid retention			
subjects affected / exposed	2 / 88 (2.27%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gout			

subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			
subjects affected / exposed	0 / 88 (0.00%)	3 / 176 (1.70%)	4 / 177 (2.26%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoalbuminaemia			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	1 / 88 (1.14%)	2 / 176 (1.14%)	2 / 177 (1.13%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypomagnesaemia			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 88 (0.00%)	4 / 176 (2.27%)	4 / 177 (2.26%)
occurrences causally related to treatment / all	0 / 0	0 / 5	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypovolaemia			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Tafamidis 20 mg	Tafamidis 80 mg	Placebo
Total subjects affected by non-serious adverse events			
subjects affected / exposed	86 / 88 (97.73%)	170 / 176 (96.59%)	171 / 177 (96.61%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acrochordon			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Basal cell carcinoma			
subjects affected / exposed	4 / 88 (4.55%)	4 / 176 (2.27%)	4 / 177 (2.26%)
occurrences (all)	5	9	4
Bladder neoplasm			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Cancer pain			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Haemangioma of skin			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Malignant melanoma			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Melanocytic naevus			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Metastatic squamous cell carcinoma			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Neoplasm			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Neoplasm skin			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Neuroendocrine carcinoma of the skin			

subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Ocular neoplasm			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Prostate cancer			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	3	1
Seborrhoeic keratosis			
subjects affected / exposed	1 / 88 (1.14%)	2 / 176 (1.14%)	0 / 177 (0.00%)
occurrences (all)	1	2	0
Squamous cell carcinoma			
subjects affected / exposed	0 / 88 (0.00%)	5 / 176 (2.84%)	2 / 177 (1.13%)
occurrences (all)	0	6	4
Squamous cell carcinoma of skin			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	2 / 177 (1.13%)
occurrences (all)	0	2	2
Vascular disorders			
Aortic aneurysm			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Aortic dilatation			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Aortic stenosis			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	2 / 177 (1.13%)
occurrences (all)	0	0	3
Arterial occlusive disease			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Arteriosclerosis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Bleeding varicose vein			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	1	1	2

Deep vein thrombosis			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Embolism			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Haematoma			
subjects affected / exposed	2 / 88 (2.27%)	6 / 176 (3.41%)	8 / 177 (4.52%)
occurrences (all)	2	6	9
Haemorrhage			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Hypertension			
subjects affected / exposed	1 / 88 (1.14%)	3 / 176 (1.70%)	4 / 177 (2.26%)
occurrences (all)	1	3	4
Hypotension			
subjects affected / exposed	11 / 88 (12.50%)	19 / 176 (10.80%)	17 / 177 (9.60%)
occurrences (all)	12	22	18
Jugular vein distension			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Lymphoedema			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Orthostatic hypotension			
subjects affected / exposed	2 / 88 (2.27%)	8 / 176 (4.55%)	5 / 177 (2.82%)
occurrences (all)	2	10	5
Pallor			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Peripheral arterial occlusive disease			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	1	1	1
Peripheral coldness			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	1	0	1

Peripheral vascular disorder			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	2
Peripheral venous disease			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Raynaud's phenomenon			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	2 / 177 (1.13%)
occurrences (all)	0	0	2
Subclavian vein thrombosis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Thrombosis			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Varicophlebitis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Varicose vein			
subjects affected / exposed	2 / 88 (2.27%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	2	1	1
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	11 / 88 (12.50%)	16 / 176 (9.09%)	11 / 177 (6.21%)
occurrences (all)	16	20	17
Atrophy			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	0 / 177 (0.00%)
occurrences (all)	0	2	0
Chest discomfort			
subjects affected / exposed	3 / 88 (3.41%)	8 / 176 (4.55%)	8 / 177 (4.52%)
occurrences (all)	3	8	9
Chest pain			
subjects affected / exposed	3 / 88 (3.41%)	7 / 176 (3.98%)	8 / 177 (4.52%)
occurrences (all)	3	7	9
Chills			

subjects affected / exposed	2 / 88 (2.27%)	2 / 176 (1.14%)	2 / 177 (1.13%)
occurrences (all)	2	3	2
Condition aggravated			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Cyst rupture			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Decreased activity			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Discomfort			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Disease progression			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	2
Early satiety			
subjects affected / exposed	2 / 88 (2.27%)	2 / 176 (1.14%)	3 / 177 (1.69%)
occurrences (all)	2	2	3
Effusion			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Exercise tolerance decreased			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	4 / 177 (2.26%)
occurrences (all)	0	1	10
Facial pain			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	2	0	0
Fatigue			
subjects affected / exposed	16 / 88 (18.18%)	29 / 176 (16.48%)	33 / 177 (18.64%)
occurrences (all)	23	33	48
Feeling abnormal			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Feeling cold			

subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Gait disturbance			
subjects affected / exposed	4 / 88 (4.55%)	4 / 176 (2.27%)	11 / 177 (6.21%)
occurrences (all)	4	4	11
General physical health deterioration			
subjects affected / exposed	1 / 88 (1.14%)	4 / 176 (2.27%)	1 / 177 (0.56%)
occurrences (all)	4	4	1
Generalised oedema			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Ill-defined disorder			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Impaired healing			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	2 / 177 (1.13%)
occurrences (all)	1	1	2
Implant site haematoma			
subjects affected / exposed	2 / 88 (2.27%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	2	0	1
Implant site pain			
subjects affected / exposed	2 / 88 (2.27%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	2	1	1
Inflammation			
subjects affected / exposed	0 / 88 (0.00%)	3 / 176 (1.70%)	1 / 177 (0.56%)
occurrences (all)	0	4	1
Influenza like illness			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Malaise			
subjects affected / exposed	1 / 88 (1.14%)	2 / 176 (1.14%)	4 / 177 (2.26%)
occurrences (all)	1	2	5
Mass			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Multiple organ dysfunction syndrome			

subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Non-cardiac chest pain			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	1	1	0
Oedema			
subjects affected / exposed	7 / 88 (7.95%)	11 / 176 (6.25%)	20 / 177 (11.30%)
occurrences (all)	7	22	22
Oedema peripheral			
subjects affected / exposed	17 / 88 (19.32%)	29 / 176 (16.48%)	31 / 177 (17.51%)
occurrences (all)	19	42	42
Pain			
subjects affected / exposed	1 / 88 (1.14%)	6 / 176 (3.41%)	2 / 177 (1.13%)
occurrences (all)	1	6	2
Peripheral swelling			
subjects affected / exposed	2 / 88 (2.27%)	6 / 176 (3.41%)	7 / 177 (3.95%)
occurrences (all)	3	7	7
Pseudocyst			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Pyrexia			
subjects affected / exposed	1 / 88 (1.14%)	3 / 176 (1.70%)	4 / 177 (2.26%)
occurrences (all)	2	3	4
Systemic inflammatory response syndrome			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Temperature intolerance			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	1	1	0
Haemorrhagic cyst			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Immune system disorders			
Dust allergy			

subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Hypersensitivity			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Seasonal allergy			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	0 / 177 (0.00%)
occurrences (all)	0	2	0
Type IV hypersensitivity reaction			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Social circumstances			
Immobile			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Reproductive system and breast disorders			
Benign prostatic hyperplasia			
subjects affected / exposed	2 / 88 (2.27%)	6 / 176 (3.41%)	7 / 177 (3.95%)
occurrences (all)	2	7	7
Breast engorgement			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Breast enlargement			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Breast mass			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	1	1	1
Breast pain			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Breast swelling			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Breast tenderness			

subjects affected / exposed	1 / 88 (1.14%)	5 / 176 (2.84%)	3 / 177 (1.69%)
occurrences (all)	1	5	3
Cervix disorder			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Erectile dysfunction			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	3 / 177 (1.69%)
occurrences (all)	0	2	3
Genital rash			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Gynaecomastia			
subjects affected / exposed	4 / 88 (4.55%)	9 / 176 (5.11%)	6 / 177 (3.39%)
occurrences (all)	4	9	6
Nipple pain			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	3 / 177 (1.69%)
occurrences (all)	1	1	3
Oedema genital			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Pelvic pain			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Penile haemorrhage			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Prostatomegaly			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Scrotal oedema			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			

subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	1	1	0
Apnoea			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Asthma			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Atelectasis			
subjects affected / exposed	0 / 88 (0.00%)	3 / 176 (1.70%)	3 / 177 (1.69%)
occurrences (all)	0	3	3
Bronchial disorder			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	0 / 177 (0.00%)
occurrences (all)	0	2	0
Bronchial hyperreactivity			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Bronchitis chronic			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Bronchospasm			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Cheyne-Stokes respiration			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	1 / 177 (0.56%)
occurrences (all)	0	2	1
Chronic obstructive pulmonary disease			
subjects affected / exposed	2 / 88 (2.27%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	2	1	1
Cough			
subjects affected / exposed	16 / 88 (18.18%)	20 / 176 (11.36%)	30 / 177 (16.95%)
occurrences (all)	23	27	35
Dyspnoea			
subjects affected / exposed	21 / 88 (23.86%)	27 / 176 (15.34%)	51 / 177 (28.81%)
occurrences (all)	26	38	69

Dyspnoea at rest			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Dyspnoea exertional			
subjects affected / exposed	5 / 88 (5.68%)	10 / 176 (5.68%)	13 / 177 (7.34%)
occurrences (all)	5	11	16
Dyspnoea paroxysmal nocturnal			
subjects affected / exposed	0 / 88 (0.00%)	3 / 176 (1.70%)	5 / 177 (2.82%)
occurrences (all)	0	4	7
Emphysema			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Epistaxis			
subjects affected / exposed	2 / 88 (2.27%)	12 / 176 (6.82%)	14 / 177 (7.91%)
occurrences (all)	3	12	22
Haemoptysis			
subjects affected / exposed	2 / 88 (2.27%)	3 / 176 (1.70%)	3 / 177 (1.69%)
occurrences (all)	2	3	3
Hyperventilation			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Hypoxia			
subjects affected / exposed	1 / 88 (1.14%)	2 / 176 (1.14%)	3 / 177 (1.69%)
occurrences (all)	1	2	3
Laryngeal disorder			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Increased upper airway secretion			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Laryngeal erythema			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Lower respiratory tract congestion			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0

Lung disorder			
subjects affected / exposed	0 / 88 (0.00%)	3 / 176 (1.70%)	0 / 177 (0.00%)
occurrences (all)	0	4	0
Lung infiltration			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Nasal congestion			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	3 / 177 (1.69%)
occurrences (all)	0	1	3
Nasal dryness			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Nasal inflammation			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Nasal mucosal disorder			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Obstructive airways disorder			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Oropharyngeal discomfort			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Oropharyngeal pain			
subjects affected / exposed	0 / 88 (0.00%)	4 / 176 (2.27%)	4 / 177 (2.26%)
occurrences (all)	0	4	4
Orthopnoea			
subjects affected / exposed	0 / 88 (0.00%)	5 / 176 (2.84%)	4 / 177 (2.26%)
occurrences (all)	0	7	4
Painful respiration			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Pleural effusion			
subjects affected / exposed	8 / 88 (9.09%)	12 / 176 (6.82%)	31 / 177 (17.51%)
occurrences (all)	11	16	42

Pleuritic pain			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Pneumomediastinum			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Pneumothorax			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	2 / 177 (1.13%)
occurrences (all)	1	2	2
Productive cough			
subjects affected / exposed	2 / 88 (2.27%)	7 / 176 (3.98%)	2 / 177 (1.13%)
occurrences (all)	2	7	2
Pulmonary congestion			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	2 / 177 (1.13%)
occurrences (all)	0	1	2
Pulmonary embolism			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	1	1	0
Pulmonary hypertension			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	2 / 177 (1.13%)
occurrences (all)	0	2	2
Pulmonary mass			
subjects affected / exposed	1 / 88 (1.14%)	3 / 176 (1.70%)	0 / 177 (0.00%)
occurrences (all)	2	3	0
Pulmonary oedema			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	4 / 177 (2.26%)
occurrences (all)	1	0	4
Rales			
subjects affected / exposed	3 / 88 (3.41%)	2 / 176 (1.14%)	3 / 177 (1.69%)
occurrences (all)	3	2	3
Reflux laryngitis			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Respiratory disorder			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	1	0	1

Respiratory distress			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Respiratory failure			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	3 / 177 (1.69%)
occurrences (all)	0	0	3
Respiratory tract congestion			
subjects affected / exposed	2 / 88 (2.27%)	1 / 176 (0.57%)	2 / 177 (1.13%)
occurrences (all)	2	2	2
Rhinitis allergic			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	2 / 177 (1.13%)
occurrences (all)	1	0	2
Rhinorrhoea			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	4 / 177 (2.26%)
occurrences (all)	0	1	4
Rhonchi			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Sinus congestion			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	2 / 177 (1.13%)
occurrences (all)	0	0	2
Sleep apnoea syndrome			
subjects affected / exposed	2 / 88 (2.27%)	8 / 176 (4.55%)	6 / 177 (3.39%)
occurrences (all)	2	9	10
Sneezing			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Sputum retention			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	2 / 177 (1.13%)
occurrences (all)	0	0	2
Upper respiratory tract congestion			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Upper-airway cough syndrome			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0

Vasomotor rhinitis			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	2	0	1
Vocal cord dysfunction			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Wheezing			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	2 / 177 (1.13%)
occurrences (all)	2	1	3
Dysphonia			
subjects affected / exposed	2 / 88 (2.27%)	1 / 176 (0.57%)	2 / 177 (1.13%)
occurrences (all)	2	1	2
Psychiatric disorders			
Acrophobia			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Adjustment disorder			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	2 / 177 (1.13%)
occurrences (all)	0	0	2
Agitation			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	1	1	0
Anxiety			
subjects affected / exposed	1 / 88 (1.14%)	8 / 176 (4.55%)	5 / 177 (2.82%)
occurrences (all)	1	8	6
Cardiovascular somatic symptom disorder			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Confusional state			
subjects affected / exposed	1 / 88 (1.14%)	3 / 176 (1.70%)	4 / 177 (2.26%)
occurrences (all)	2	3	4
Delirium			
subjects affected / exposed	1 / 88 (1.14%)	3 / 176 (1.70%)	3 / 177 (1.69%)
occurrences (all)	1	3	3
Depressed mood			

subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	3 / 177 (1.69%)
occurrences (all)	0	0	3
Depression			
subjects affected / exposed	6 / 88 (6.82%)	7 / 176 (3.98%)	8 / 177 (4.52%)
occurrences (all)	6	7	10
Disorientation			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Dysphemia			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Hallucination			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	1	1	1
Insomnia			
subjects affected / exposed	12 / 88 (13.64%)	20 / 176 (11.36%)	22 / 177 (12.43%)
occurrences (all)	13	23	27
Major depression			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	2
Mental status changes			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Nervousness			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Nightmare			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Organic brain syndrome			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Panic attack			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Persecutory delusion			

subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Restlessness			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Sleep disorder			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	1	1	0
Stress			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	2
Product issues			
Device computer issue			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Device dislocation			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	2 / 177 (1.13%)
occurrences (all)	0	0	2
Device inappropriate shock delivery			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Device loosening			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Device malfunction			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	2	0
Device stimulation issue			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	2 / 177 (1.13%)
occurrences (all)	0	0	3
Hepatobiliary disorders			
Bile duct stenosis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Cholecystitis			

subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Cholelithiasis			
subjects affected / exposed	4 / 88 (4.55%)	0 / 176 (0.00%)	2 / 177 (1.13%)
occurrences (all)	4	0	2
Cholestasis			
subjects affected / exposed	1 / 88 (1.14%)	2 / 176 (1.14%)	1 / 177 (0.56%)
occurrences (all)	1	2	1
Hepatic cirrhosis			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Hepatic cyst			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Hepatic congestion			
subjects affected / exposed	2 / 88 (2.27%)	4 / 176 (2.27%)	2 / 177 (1.13%)
occurrences (all)	2	4	2
Hepatic pain			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Hepatic steatosis			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	2 / 177 (1.13%)
occurrences (all)	0	0	2
Hepatitis acute			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Hepatomegaly			
subjects affected / exposed	1 / 88 (1.14%)	3 / 176 (1.70%)	1 / 177 (0.56%)
occurrences (all)	1	3	1
Ischaemic hepatitis			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Jaundice			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Jaundice cholestatic			

subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Portal vein thrombosis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Hyperbilirubinaemia			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	2 / 177 (1.13%)
occurrences (all)	1	2	3
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Anticoagulation drug level above therapeutic			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	4 / 177 (2.26%)
occurrences (all)	0	1	4
Anticoagulation drug level below therapeutic			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	1	1	0
Arterial bruit			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 88 (0.00%)	3 / 176 (1.70%)	1 / 177 (0.56%)
occurrences (all)	0	3	1
Bence Jones protein urine present			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Blood albumin decreased			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	1	0	1
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	2 / 177 (1.13%)
occurrences (all)	0	1	2
Blood bicarbonate decreased			

subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Blood bilirubin increased			
subjects affected / exposed	4 / 88 (4.55%)	3 / 176 (1.70%)	1 / 177 (0.56%)
occurrences (all)	4	4	1
Blood chloride decreased			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Blood creatine increased			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Blood creatinine abnormal			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Blood creatinine increased			
subjects affected / exposed	3 / 88 (3.41%)	9 / 176 (5.11%)	8 / 177 (4.52%)
occurrences (all)	4	9	8
Blood glucose increased			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	1 / 177 (0.56%)
occurrences (all)	0	2	1
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Blood lactic acid increased			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Blood potassium abnormal			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	2 / 177 (1.13%)
occurrences (all)	0	0	2
Blood potassium decreased			

subjects affected / exposed	1 / 88 (1.14%)	4 / 176 (2.27%)	5 / 177 (2.82%)
occurrences (all)	1	4	5
Blood potassium increased			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	4 / 177 (2.26%)
occurrences (all)	0	0	4
Blood pressure decreased			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	2 / 177 (1.13%)
occurrences (all)	0	0	2
Blood pressure increased			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Blood pressure systolic decreased			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Blood sodium decreased			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Blood thyroid stimulating hormone decreased			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Blood thyroid stimulating hormone increased			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	5 / 177 (2.82%)
occurrences (all)	0	1	5
Blood urea increased			
subjects affected / exposed	3 / 88 (3.41%)	8 / 176 (4.55%)	5 / 177 (2.82%)
occurrences (all)	3	8	5
Blood uric acid increased			
subjects affected / exposed	3 / 88 (3.41%)	8 / 176 (4.55%)	5 / 177 (2.82%)
occurrences (all)	3	8	5
Blood urine present			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	0 / 177 (0.00%)
occurrences (all)	0	2	0
Body temperature decreased			

subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	0 / 177 (0.00%)
occurrences (all)	0	2	0
Breath sounds abnormal			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	3 / 177 (1.69%)
occurrences (all)	0	1	3
C-reactive protein increased			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Cardiac murmur			
subjects affected / exposed	2 / 88 (2.27%)	3 / 176 (1.70%)	4 / 177 (2.26%)
occurrences (all)	2	3	4
Crystal urine present			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Drug level above therapeutic			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Ejection fraction decreased			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	5 / 177 (2.82%)
occurrences (all)	0	2	5
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Electrocardiogram abnormal			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Gamma-glutamyltransferase increased			
subjects affected / exposed	3 / 88 (3.41%)	9 / 176 (5.11%)	11 / 177 (6.21%)
occurrences (all)	3	9	11
Glomerular filtration rate decreased			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Haemoglobin decreased			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1

Heart rate decreased			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Heart rate increased			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	2 / 177 (1.13%)
occurrences (all)	0	0	2
Heart rate irregular			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Hepatic enzyme increased			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Human epidermal growth factor receptor decreased			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Human rhinovirus test positive			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Inflammatory marker increased			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
International normalised ratio decreased			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
International normalised ratio increased			
subjects affected / exposed	5 / 88 (5.68%)	4 / 176 (2.27%)	4 / 177 (2.26%)
occurrences (all)	6	4	4
Liver function test abnormal			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	2 / 177 (1.13%)
occurrences (all)	0	0	2
Liver function test increased			
subjects affected / exposed	2 / 88 (2.27%)	5 / 176 (2.84%)	2 / 177 (1.13%)
occurrences (all)	2	5	2
N-terminal prohormone brain natriuretic peptide increased			

subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	1 / 177 (0.56%)
occurrences (all)	0	2	1
Occult blood positive			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	2 / 177 (1.13%)
occurrences (all)	0	0	2
Optic nerve cup/disc ratio increased			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Oxygen saturation abnormal			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	2 / 177 (1.13%)
occurrences (all)	0	2	2
Oxygen saturation decreased			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	2
Platelet count decreased			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	2 / 177 (1.13%)
occurrences (all)	1	1	2
Prostatic specific antigen increased			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	2 / 177 (1.13%)
occurrences (all)	0	0	2
Protein urine present			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Prothrombin time prolonged			
subjects affected / exposed	3 / 88 (3.41%)	3 / 176 (1.70%)	1 / 177 (0.56%)
occurrences (all)	3	3	1
Pulmonary function test decreased			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Pulse absent			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Red blood cell count decreased			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Thyroid function test abnormal			

subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Thyroxine decreased			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Transaminases increased			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	3 / 177 (1.69%)
occurrences (all)	0	2	4
Troponin increased			
subjects affected / exposed	1 / 88 (1.14%)	2 / 176 (1.14%)	4 / 177 (2.26%)
occurrences (all)	1	2	4
Urobilinogen urine increased			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Venous pressure jugular abnormal			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Venous pressure jugular increased			
subjects affected / exposed	4 / 88 (4.55%)	4 / 176 (2.27%)	9 / 177 (5.08%)
occurrences (all)	5	4	12
Vitamin D decreased			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	2 / 177 (1.13%)
occurrences (all)	0	2	2
Waist circumference increased			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	0 / 177 (0.00%)
occurrences (all)	0	2	0
Weight decreased			
subjects affected / exposed	6 / 88 (6.82%)	8 / 176 (4.55%)	18 / 177 (10.17%)
occurrences (all)	6	8	19
Weight increased			
subjects affected / exposed	7 / 88 (7.95%)	13 / 176 (7.39%)	12 / 177 (6.78%)
occurrences (all)	8	20	12
White blood cell count decreased			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Injury, poisoning and procedural			

complications			
Abdominal injury			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Animal bite			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Arthropod bite			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Arthropod sting			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Back injury			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Bone fissure			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Bursa injury			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	2
Cervical vertebral fracture			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	1	0	1
Chest injury			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Compression fracture			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Contusion			
subjects affected / exposed	6 / 88 (6.82%)	11 / 176 (6.25%)	5 / 177 (2.82%)
occurrences (all)	6	14	6
Craniocerebral injury			

subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	1	0	2
Electric shock			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Excoriation			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Eye contusion			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Face injury			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Facial bones fracture			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	1	1	0
Fall			
subjects affected / exposed	24 / 88 (27.27%)	38 / 176 (21.59%)	40 / 177 (22.60%)
occurrences (all)	36	50	69
Femoral neck fracture			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Femur fracture			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Foot fracture			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Hand fracture			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	2 / 177 (1.13%)
occurrences (all)	0	1	2
Head injury			
subjects affected / exposed	1 / 88 (1.14%)	5 / 176 (2.84%)	2 / 177 (1.13%)
occurrences (all)	1	5	2
Hip fracture			

subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	1	0	1
Incision site erythema			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Incision site pain			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	2	1
Injury			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	1	1	0
Joint injury			
subjects affected / exposed	0 / 88 (0.00%)	3 / 176 (1.70%)	1 / 177 (0.56%)
occurrences (all)	0	3	1
Laceration			
subjects affected / exposed	3 / 88 (3.41%)	6 / 176 (3.41%)	3 / 177 (1.69%)
occurrences (all)	3	6	3
Ligament injury			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Ligament sprain			
subjects affected / exposed	2 / 88 (2.27%)	1 / 176 (0.57%)	2 / 177 (1.13%)
occurrences (all)	2	1	2
Limb injury			
subjects affected / exposed	2 / 88 (2.27%)	1 / 176 (0.57%)	4 / 177 (2.26%)
occurrences (all)	2	1	4
Lip injury			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Lower limb fracture			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Lumbar vertebral fracture			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Meniscus injury			

subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	1	1	0
Metal poisoning			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Muscle injury			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	1	0	1
Muscle rupture			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Muscle strain			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	2 / 177 (1.13%)
occurrences (all)	0	0	2
Overdose			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Pelvic fracture			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Periorbital haemorrhage			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Post procedural haematoma			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Post procedural haemorrhage			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	2 / 177 (1.13%)
occurrences (all)	0	1	2
Post procedural swelling			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Procedural pain			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	2 / 177 (1.13%)
occurrences (all)	0	2	4
Rib fracture			

subjects affected / exposed	2 / 88 (2.27%)	2 / 176 (1.14%)	3 / 177 (1.69%)
occurrences (all)	2	2	4
Scar			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	0 / 177 (0.00%)
occurrences (all)	0	2	0
Seroma			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Skeletal injury			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Skin abrasion			
subjects affected / exposed	1 / 88 (1.14%)	5 / 176 (2.84%)	5 / 177 (2.82%)
occurrences (all)	1	5	5
Skin injury			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Spinal column injury			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Spinal compression fracture			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	2 / 177 (1.13%)
occurrences (all)	1	0	2
Subcutaneous haematoma			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Subdural haematoma			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	3	0
Sunburn			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Suture related complication			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Thermal burn			

subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	2
Thoracic vertebral fracture			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Tooth fracture			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Upper limb fracture			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Wound			
subjects affected / exposed	0 / 88 (0.00%)	4 / 176 (2.27%)	1 / 177 (0.56%)
occurrences (all)	0	4	1
Wrist fracture			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Skin wound			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Congenital, familial and genetic disorders			
Dermoid cyst			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Hydrocele			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Phimosis			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Cardiac disorders			
Accelerated idioventricular rhythm			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Acute myocardial infarction			

subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Angina pectoris			
subjects affected / exposed	2 / 88 (2.27%)	3 / 176 (1.70%)	1 / 177 (0.56%)
occurrences (all)	2	3	1
Aortic valve incompetence			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	2 / 177 (1.13%)
occurrences (all)	0	1	2
Aortic valve stenosis			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	2 / 177 (1.13%)
occurrences (all)	0	0	2
Arrhythmia			
subjects affected / exposed	0 / 88 (0.00%)	5 / 176 (2.84%)	1 / 177 (0.56%)
occurrences (all)	0	5	1
Arrhythmia supraventricular			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	3 / 177 (1.69%)
occurrences (all)	0	5	6
Arteriosclerosis coronary artery			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Atrial fibrillation			
subjects affected / exposed	13 / 88 (14.77%)	28 / 176 (15.91%)	31 / 177 (17.51%)
occurrences (all)	17	35	49
Atrial flutter			
subjects affected / exposed	5 / 88 (5.68%)	8 / 176 (4.55%)	12 / 177 (6.78%)
occurrences (all)	7	11	16
Atrial tachycardia			
subjects affected / exposed	3 / 88 (3.41%)	6 / 176 (3.41%)	7 / 177 (3.95%)
occurrences (all)	5	6	8
Atrial thrombosis			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	4 / 177 (2.26%)
occurrences (all)	1	1	4
Atrioventricular block			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	1	1	0
Atrioventricular block complete			

subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	3 / 177 (1.69%)
occurrences (all)	0	2	3
Atrioventricular block first degree			
subjects affected / exposed	2 / 88 (2.27%)	3 / 176 (1.70%)	2 / 177 (1.13%)
occurrences (all)	2	3	2
Atrioventricular block second degree			
subjects affected / exposed	1 / 88 (1.14%)	2 / 176 (1.14%)	0 / 177 (0.00%)
occurrences (all)	1	2	0
Bradyarrhythmia			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Bradycardia			
subjects affected / exposed	1 / 88 (1.14%)	2 / 176 (1.14%)	3 / 177 (1.69%)
occurrences (all)	2	2	3
Bundle branch block right			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	2 / 177 (1.13%)
occurrences (all)	0	1	2
Cardiac amyloidosis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Cardiac aneurysm			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Cardiac disorder			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Cardiac failure			
subjects affected / exposed	18 / 88 (20.45%)	20 / 176 (11.36%)	33 / 177 (18.64%)
occurrences (all)	35	29	62
Cardiac failure acute			
subjects affected / exposed	0 / 88 (0.00%)	3 / 176 (1.70%)	2 / 177 (1.13%)
occurrences (all)	0	3	6
Cardiac failure chronic			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	3
Cardiac failure congestive			

subjects affected / exposed	2 / 88 (2.27%)	3 / 176 (1.70%)	4 / 177 (2.26%)
occurrences (all)	2	3	5
Cardiogenic shock			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Cardiomegaly			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Cardiomyopathy			
subjects affected / exposed	2 / 88 (2.27%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	2	0	1
Cardiorenal syndrome			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Coronary artery disease			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	0 / 177 (0.00%)
occurrences (all)	0	2	0
Cyanosis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	3 / 177 (1.69%)
occurrences (all)	0	1	3
Diastolic dysfunction			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Hepatojugular reflux			
subjects affected / exposed	2 / 88 (2.27%)	3 / 176 (1.70%)	1 / 177 (0.56%)
occurrences (all)	2	4	1
Intracardiac thrombus			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	1	1	0
Left ventricular dysfunction			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Left ventricular failure			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	2 / 177 (1.13%)
occurrences (all)	0	1	2
Low cardiac output syndrome			

subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	2 / 177 (1.13%)
occurrences (all)	0	0	2
Mitral valve incompetence			
subjects affected / exposed	1 / 88 (1.14%)	2 / 176 (1.14%)	6 / 177 (3.39%)
occurrences (all)	1	2	7
Palpitations			
subjects affected / exposed	2 / 88 (2.27%)	4 / 176 (2.27%)	8 / 177 (4.52%)
occurrences (all)	2	4	11
Pericardial effusion			
subjects affected / exposed	2 / 88 (2.27%)	2 / 176 (1.14%)	2 / 177 (1.13%)
occurrences (all)	2	2	2
Pulmonary valve incompetence			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Rhythm idioventricular			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Right ventricular failure			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	1	1	0
Sinus arrest			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	1	1	0
Sinus bradycardia			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	1	1	0
Supraventricular extrasystoles			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Sinus node dysfunction			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	3 / 177 (1.69%)
occurrences (all)	0	1	3
Tachyarrhythmia			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	2	0	0
Supraventricular tachycardia			

subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	1 / 177 (0.56%)
occurrences (all)	0	2	1
Tachycardia			
subjects affected / exposed	3 / 88 (3.41%)	6 / 176 (3.41%)	1 / 177 (0.56%)
occurrences (all)	3	6	1
Tricuspid valve incompetence			
subjects affected / exposed	1 / 88 (1.14%)	2 / 176 (1.14%)	4 / 177 (2.26%)
occurrences (all)	1	2	4
Ventricular arrhythmia			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Ventricular extrasystoles			
subjects affected / exposed	0 / 88 (0.00%)	3 / 176 (1.70%)	3 / 177 (1.69%)
occurrences (all)	0	3	3
Ventricular fibrillation			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Ventricular tachycardia			
subjects affected / exposed	2 / 88 (2.27%)	5 / 176 (2.84%)	6 / 177 (3.39%)
occurrences (all)	3	8	6
Nervous system disorders			
Ageusia			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	3 / 177 (1.69%)
occurrences (all)	0	2	4
Altered state of consciousness			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Amnesia			
subjects affected / exposed	2 / 88 (2.27%)	4 / 176 (2.27%)	3 / 177 (1.69%)
occurrences (all)	2	4	3
Anosmia			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Aphasia			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	1	1	0

Aphonia			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Asterixis			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Ataxia			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Balance disorder			
subjects affected / exposed	2 / 88 (2.27%)	15 / 176 (8.52%)	2 / 177 (1.13%)
occurrences (all)	3	16	2
Brain injury			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Burning sensation			
subjects affected / exposed	2 / 88 (2.27%)	2 / 176 (1.14%)	0 / 177 (0.00%)
occurrences (all)	2	2	0
Carotid artery aneurysm			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Carpal tunnel syndrome			
subjects affected / exposed	5 / 88 (5.68%)	4 / 176 (2.27%)	4 / 177 (2.26%)
occurrences (all)	5	4	6
Cognitive disorder			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	3 / 177 (1.69%)
occurrences (all)	0	0	3
Dementia			
subjects affected / exposed	2 / 88 (2.27%)	1 / 176 (0.57%)	4 / 177 (2.26%)
occurrences (all)	2	1	4
Disturbance in attention			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Dizziness			
subjects affected / exposed	16 / 88 (18.18%)	25 / 176 (14.20%)	32 / 177 (18.08%)
occurrences (all)	20	31	36

Dizziness postural			
subjects affected / exposed	0 / 88 (0.00%)	4 / 176 (2.27%)	7 / 177 (3.95%)
occurrences (all)	0	5	8
Dysarthria			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Dysgeusia			
subjects affected / exposed	1 / 88 (1.14%)	3 / 176 (1.70%)	4 / 177 (2.26%)
occurrences (all)	1	3	4
Encephalopathy			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	2 / 177 (1.13%)
occurrences (all)	0	2	2
Focal dyscognitive seizures			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Head discomfort			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	1	1	1
Headache			
subjects affected / exposed	1 / 88 (1.14%)	9 / 176 (5.11%)	11 / 177 (6.21%)
occurrences (all)	1	11	13
Hemiparesis			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	1	1	0
Hypersomnia			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	2 / 177 (1.13%)
occurrences (all)	0	0	2
Hypoaesthesia			
subjects affected / exposed	5 / 88 (5.68%)	4 / 176 (2.27%)	6 / 177 (3.39%)
occurrences (all)	5	4	6
Hypotonia			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Incoherent			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0

Intention tremor			
subjects affected / exposed	3 / 88 (3.41%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	3	1	0
Lacunar infarction			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Lethargy			
subjects affected / exposed	0 / 88 (0.00%)	3 / 176 (1.70%)	3 / 177 (1.69%)
occurrences (all)	0	3	3
Loss of consciousness			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	2 / 177 (1.13%)
occurrences (all)	0	0	3
Lumbar radiculopathy			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	0 / 177 (0.00%)
occurrences (all)	0	2	0
Lumbosacral radiculopathy			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Memory impairment			
subjects affected / exposed	4 / 88 (4.55%)	5 / 176 (2.84%)	4 / 177 (2.26%)
occurrences (all)	5	5	4
Mental impairment			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Myelopathy			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Nerve compression			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Neuralgia			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Neurodegenerative disorder			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1

Neuropathy peripheral			
subjects affected / exposed	4 / 88 (4.55%)	3 / 176 (1.70%)	12 / 177 (6.78%)
occurrences (all)	4	4	14
Orthostatic intolerance			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Paraesthesia			
subjects affected / exposed	1 / 88 (1.14%)	5 / 176 (2.84%)	6 / 177 (3.39%)
occurrences (all)	1	6	6
Parkinson's disease			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Parkinsonism			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Parosmia			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Polyneuropathy			
subjects affected / exposed	1 / 88 (1.14%)	2 / 176 (1.14%)	2 / 177 (1.13%)
occurrences (all)	1	2	2
Poor quality sleep			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Presyncope			
subjects affected / exposed	2 / 88 (2.27%)	3 / 176 (1.70%)	6 / 177 (3.39%)
occurrences (all)	2	3	6
Radiculopathy			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Restless legs syndrome			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	5 / 177 (2.82%)
occurrences (all)	0	1	6
Sciatica			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	3 / 177 (1.69%)
occurrences (all)	0	2	3

Seizure			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Senile dementia			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Sensorimotor disorder			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Somnolence			
subjects affected / exposed	1 / 88 (1.14%)	2 / 176 (1.14%)	6 / 177 (3.39%)
occurrences (all)	1	2	6
Syncope			
subjects affected / exposed	5 / 88 (5.68%)	5 / 176 (2.84%)	11 / 177 (6.21%)
occurrences (all)	8	6	14
Tension headache			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Tinel's sign			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	1	0	1
Toxic encephalopathy			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Transient ischaemic attack			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	1	0	1
Tremor			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	8 / 177 (4.52%)
occurrences (all)	0	0	8
Tunnel vision			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	2	0
Visual field defect			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0

Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	5 / 88 (5.68%)	10 / 176 (5.68%)	13 / 177 (7.34%)
occurrences (all)	5	10	13
Anaemia macrocytic			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Coagulopathy			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	1	0	1
Haemorrhagic disorder			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Heparin-induced thrombocytopenia			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Hypoprothrombinaemia			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Iron deficiency anaemia			
subjects affected / exposed	0 / 88 (0.00%)	3 / 176 (1.70%)	3 / 177 (1.69%)
occurrences (all)	0	4	3
Leukocytosis			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	1	1	1
Leukopenia			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Lymphadenopathy			
subjects affected / exposed	2 / 88 (2.27%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	2	1	1
Macrocytosis			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Microcytic anaemia			

subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Neutrophilia			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Normocytic anaemia			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Splenic infarction			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Splenomegaly			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Thrombocytopenia			
subjects affected / exposed	1 / 88 (1.14%)	6 / 176 (3.41%)	5 / 177 (2.82%)
occurrences (all)	1	7	7
Polycythaemia			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Ear and labyrinth disorders			
Cerumen impaction			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	2 / 177 (1.13%)
occurrences (all)	1	1	2
Deafness			
subjects affected / exposed	0 / 88 (0.00%)	3 / 176 (1.70%)	0 / 177 (0.00%)
occurrences (all)	0	3	0
Deafness neurosensory			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Ear discomfort			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Ear disorder			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1

Ear haemorrhage			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	2 / 177 (1.13%)
occurrences (all)	0	0	2
Ear pain			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Eustachian tube dysfunction			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Excessive cerumen production			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Hypoacusis			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	1	1	1
Tinnitus			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	2
Vertigo			
subjects affected / exposed	1 / 88 (1.14%)	5 / 176 (2.84%)	4 / 177 (2.26%)
occurrences (all)	1	5	5
Vertigo positional			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	1	1	0
Eye disorders			
Amaurosis fugax			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	2
Blepharitis			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	2
Blepharochalasis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Cataract			

subjects affected / exposed	3 / 88 (3.41%)	8 / 176 (4.55%)	2 / 177 (1.13%)
occurrences (all)	3	8	2
Chalazion			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Conjunctival haemorrhage			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	0 / 177 (0.00%)
occurrences (all)	0	2	0
Diplopia			
subjects affected / exposed	2 / 88 (2.27%)	0 / 176 (0.00%)	2 / 177 (1.13%)
occurrences (all)	3	0	2
Dry eye			
subjects affected / exposed	0 / 88 (0.00%)	4 / 176 (2.27%)	5 / 177 (2.82%)
occurrences (all)	0	5	5
Eye disorder			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Eye haemorrhage			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	2 / 177 (1.13%)
occurrences (all)	0	1	3
Eye oedema			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Eye pruritus			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Eyelid bleeding			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Eyelid cyst			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Glaucoma			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	1	0	1
Lacrimal structural disorder			

subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Lacrimation increased			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	1	1	0
Macular degeneration			
subjects affected / exposed	2 / 88 (2.27%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	2	0	0
Macular fibrosis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Neovascular age-related macular degeneration			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Ocular hyperaemia			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Ocular vascular disorder			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Optic atrophy			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Papilloedema			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Photopsia			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Pterygium			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	2
Retinal tear			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	1	1	0

Vision blurred			
subjects affected / exposed	2 / 88 (2.27%)	5 / 176 (2.84%)	3 / 177 (1.69%)
occurrences (all)	2	5	4
Scleral discolouration			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Visual acuity reduced			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Visual impairment			
subjects affected / exposed	2 / 88 (2.27%)	3 / 176 (1.70%)	1 / 177 (0.56%)
occurrences (all)	3	4	1
Vitreous detachment			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	3 / 88 (3.41%)	6 / 176 (3.41%)	7 / 177 (3.95%)
occurrences (all)	3	6	7
Abdominal distension			
subjects affected / exposed	6 / 88 (6.82%)	7 / 176 (3.98%)	5 / 177 (2.82%)
occurrences (all)	6	10	5
Abdominal hernia			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Abdominal pain			
subjects affected / exposed	3 / 88 (3.41%)	8 / 176 (4.55%)	6 / 177 (3.39%)
occurrences (all)	3	8	6
Abdominal pain lower			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	2 / 177 (1.13%)
occurrences (all)	0	2	2
Abdominal pain upper			
subjects affected / exposed	1 / 88 (1.14%)	5 / 176 (2.84%)	5 / 177 (2.82%)
occurrences (all)	1	9	7
Abdominal wall haematoma			

subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Abdominal rigidity			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Anal incontinence			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	0 / 177 (0.00%)
occurrences (all)	0	2	0
Ascites			
subjects affected / exposed	7 / 88 (7.95%)	6 / 176 (3.41%)	9 / 177 (5.08%)
occurrences (all)	12	7	12
Barrett's oesophagus			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	2	1
Bowel movement irregularity			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Colitis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Constipation			
subjects affected / exposed	14 / 88 (15.91%)	25 / 176 (14.20%)	30 / 177 (16.95%)
occurrences (all)	15	25	36
Dental caries			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Diarrhoea			
subjects affected / exposed	10 / 88 (11.36%)	22 / 176 (12.50%)	39 / 177 (22.03%)
occurrences (all)	11	25	52
Diverticulum			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	2 / 177 (1.13%)
occurrences (all)	1	1	2
Diverticulum intestinal			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	3 / 177 (1.69%)
occurrences (all)	1	0	3
Dry mouth			

subjects affected / exposed	1 / 88 (1.14%)	2 / 176 (1.14%)	5 / 177 (2.82%)
occurrences (all)	1	2	5
Duodenal ulcer			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Dyspepsia			
subjects affected / exposed	3 / 88 (3.41%)	4 / 176 (2.27%)	5 / 177 (2.82%)
occurrences (all)	3	5	6
Dysphagia			
subjects affected / exposed	2 / 88 (2.27%)	4 / 176 (2.27%)	2 / 177 (1.13%)
occurrences (all)	2	4	3
Enteritis			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Epigastric discomfort			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	1	1	0
Eructation			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Faeces soft			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	1	0	1
Flatulence			
subjects affected / exposed	2 / 88 (2.27%)	8 / 176 (4.55%)	3 / 177 (1.69%)
occurrences (all)	3	9	3
Frequent bowel movements			
subjects affected / exposed	0 / 88 (0.00%)	3 / 176 (1.70%)	0 / 177 (0.00%)
occurrences (all)	0	3	0
Functional gastrointestinal disorder			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Gastric disorder			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	3 / 177 (1.69%)
occurrences (all)	1	1	3
Gastric ulcer			

subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Gastritis			
subjects affected / exposed	0 / 88 (0.00%)	3 / 176 (1.70%)	1 / 177 (0.56%)
occurrences (all)	0	3	2
Gastritis haemorrhagic			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	0 / 177 (0.00%)
occurrences (all)	0	2	0
Gastrointestinal angiodysplasia			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Gastrointestinal disorder			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	2 / 177 (1.13%)
occurrences (all)	0	0	2
Gastrooesophageal reflux disease			
subjects affected / exposed	6 / 88 (6.82%)	0 / 176 (0.00%)	7 / 177 (3.95%)
occurrences (all)	6	0	7
Gingival bleeding			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Haematochezia			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Haemorrhoids			
subjects affected / exposed	0 / 88 (0.00%)	4 / 176 (2.27%)	4 / 177 (2.26%)
occurrences (all)	0	5	4
Hiatus hernia			
subjects affected / exposed	1 / 88 (1.14%)	2 / 176 (1.14%)	2 / 177 (1.13%)
occurrences (all)	1	2	2
Ileus			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Impaired gastric emptying			

subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	1	1	0
Incarcerated inguinal hernia			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Inguinal hernia			
subjects affected / exposed	5 / 88 (5.68%)	5 / 176 (2.84%)	3 / 177 (1.69%)
occurrences (all)	6	5	3
Large intestine polyp			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	3 / 177 (1.69%)
occurrences (all)	1	1	4
Lower gastrointestinal haemorrhage			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Melaena			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Mouth haemorrhage			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Nausea			
subjects affected / exposed	9 / 88 (10.23%)	20 / 176 (11.36%)	36 / 177 (20.34%)
occurrences (all)	11	21	53
Oesophageal mass			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Oesophageal spasm			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Oesophagitis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	2 / 177 (1.13%)
occurrences (all)	0	1	2
Oral disorder			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Pancreatic cyst			

subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Pancreatic mass			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Periodontal disease			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Pharyngo-oesophageal diverticulum			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Pneumatosis intestinalis			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Proctalgia			
subjects affected / exposed	2 / 88 (2.27%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	2	0	0
Rectal haemorrhage			
subjects affected / exposed	1 / 88 (1.14%)	2 / 176 (1.14%)	0 / 177 (0.00%)
occurrences (all)	1	2	0
Rectal polyp			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Retching			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	2 / 177 (1.13%)
occurrences (all)	1	0	2
Salivary gland calculus			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Salivary gland enlargement			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Tooth loss			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Toothache			

subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	2 / 177 (1.13%)
occurrences (all)	0	2	2
Umbilical hernia			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	2 / 177 (1.13%)
occurrences (all)	1	0	2
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Vomiting			
subjects affected / exposed	7 / 88 (7.95%)	6 / 176 (3.41%)	16 / 177 (9.04%)
occurrences (all)	7	6	19
Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Actinic keratosis			
subjects affected / exposed	3 / 88 (3.41%)	3 / 176 (1.70%)	0 / 177 (0.00%)
occurrences (all)	3	3	0
Alopecia			
subjects affected / exposed	0 / 88 (0.00%)	3 / 176 (1.70%)	0 / 177 (0.00%)
occurrences (all)	0	3	0
Blister			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	2 / 177 (1.13%)
occurrences (all)	0	2	3
Cold sweat			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Decubitus ulcer			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	4 / 177 (2.26%)
occurrences (all)	1	0	4
Dermatitis			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	1	0	1
Dermatitis allergic			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	2

Dermatitis atopic			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	2	0
Dermatitis contact			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	1 / 177 (0.56%)
occurrences (all)	0	2	1
Diabetic foot			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Dry skin			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	1	1	0
Ecchymosis			
subjects affected / exposed	0 / 88 (0.00%)	4 / 176 (2.27%)	3 / 177 (1.69%)
occurrences (all)	0	6	3
Eczema			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	1	1	1
Eczema nummular			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	2	0
Erythema			
subjects affected / exposed	1 / 88 (1.14%)	2 / 176 (1.14%)	5 / 177 (2.82%)
occurrences (all)	1	2	5
Haemorrhage subcutaneous			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Hair colour changes			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Hyperhidrosis			
subjects affected / exposed	2 / 88 (2.27%)	4 / 176 (2.27%)	0 / 177 (0.00%)
occurrences (all)	2	5	0
Hyperkeratosis			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	1	0	1

Hypertrophic scar			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Ingrowing nail			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Lentigo			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Myxoid cyst			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Nail dystrophy			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Nail ridging			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Neurodermatitis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Night sweats			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Onychomalacia			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Petechiae			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Photodermatosis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Pigmentation disorder			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0

Post inflammatory pigmentation change			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Pruritus			
subjects affected / exposed	4 / 88 (4.55%)	12 / 176 (6.82%)	15 / 177 (8.47%)
occurrences (all)	5	14	16
Pruritus generalised			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	2 / 177 (1.13%)
occurrences (all)	0	1	2
Psoriasis			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Purpura			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Rash			
subjects affected / exposed	3 / 88 (3.41%)	6 / 176 (3.41%)	12 / 177 (6.78%)
occurrences (all)	3	6	16
Rash erythematous			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	0 / 177 (0.00%)
occurrences (all)	0	2	0
Rash pruritic			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Seborrhoeic dermatitis			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Skin atrophy			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Skin disorder			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Skin lesion			

subjects affected / exposed	0 / 88 (0.00%)	4 / 176 (2.27%)	4 / 177 (2.26%)
occurrences (all)	0	4	5
Skin ulcer			
subjects affected / exposed	3 / 88 (3.41%)	7 / 176 (3.98%)	1 / 177 (0.56%)
occurrences (all)	3	9	1
Stasis dermatitis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	2	0
Subcutaneous emphysema			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Swelling face			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Transient acantholytic dermatosis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	2	0
Xanthoma			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Papule			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Xeroderma			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Urticaria			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	1	1	0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	5 / 88 (5.68%)	8 / 176 (4.55%)	18 / 177 (10.17%)
occurrences (all)	6	11	19
Azotaemia			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	1	1	0

Calculus bladder			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	1	1	0
Chronic kidney disease			
subjects affected / exposed	4 / 88 (4.55%)	6 / 176 (3.41%)	6 / 177 (3.39%)
occurrences (all)	4	7	7
Dysuria			
subjects affected / exposed	2 / 88 (2.27%)	1 / 176 (0.57%)	2 / 177 (1.13%)
occurrences (all)	3	1	3
End stage renal disease			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Haematuria			
subjects affected / exposed	10 / 88 (11.36%)	8 / 176 (4.55%)	15 / 177 (8.47%)
occurrences (all)	13	9	17
Incontinence			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Micturition urgency			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	1	1	0
Nephrolithiasis			
subjects affected / exposed	2 / 88 (2.27%)	1 / 176 (0.57%)	3 / 177 (1.69%)
occurrences (all)	2	1	3
Neurogenic bladder			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Nocturia			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Oliguria			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Pollakiuria			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	2 / 177 (1.13%)
occurrences (all)	0	0	2

Polyuria			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	2 / 177 (1.13%)
occurrences (all)	0	0	2
Proteinuria			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	5 / 177 (2.82%)
occurrences (all)	0	2	5
Renal cyst			
subjects affected / exposed	1 / 88 (1.14%)	4 / 176 (2.27%)	2 / 177 (1.13%)
occurrences (all)	1	4	2
Renal disorder			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Renal failure			
subjects affected / exposed	5 / 88 (5.68%)	8 / 176 (4.55%)	7 / 177 (3.95%)
occurrences (all)	6	10	7
Renal impairment			
subjects affected / exposed	2 / 88 (2.27%)	5 / 176 (2.84%)	8 / 177 (4.52%)
occurrences (all)	2	5	8
Renal infarct			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Renal injury			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	2 / 177 (1.13%)
occurrences (all)	0	0	2
Renal mass			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Stress urinary incontinence			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Ureterolithiasis			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Urinary bladder polyp			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1

Urinary incontinence			
subjects affected / exposed	1 / 88 (1.14%)	2 / 176 (1.14%)	2 / 177 (1.13%)
occurrences (all)	1	2	2
Urinary retention			
subjects affected / exposed	2 / 88 (2.27%)	6 / 176 (3.41%)	12 / 177 (6.78%)
occurrences (all)	2	6	12
Urinary tract pain			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Urine flow decreased			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Urethral stenosis			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Endocrine disorders			
Hyperparathyroidism			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	2 / 177 (1.13%)
occurrences (all)	1	0	2
Hyperparathyroidism secondary			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Hyperthyroidism			
subjects affected / exposed	0 / 88 (0.00%)	3 / 176 (1.70%)	2 / 177 (1.13%)
occurrences (all)	0	3	2
Hypogonadism			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Hypothyroidism			
subjects affected / exposed	5 / 88 (5.68%)	12 / 176 (6.82%)	10 / 177 (5.65%)
occurrences (all)	6	12	10
Thyroid mass			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	1	1	1
Musculoskeletal and connective tissue disorders			

Arthralgia			
subjects affected / exposed	8 / 88 (9.09%)	17 / 176 (9.66%)	20 / 177 (11.30%)
occurrences (all)	11	19	27
Arthritis			
subjects affected / exposed	4 / 88 (4.55%)	4 / 176 (2.27%)	1 / 177 (0.56%)
occurrences (all)	4	4	1
Back pain			
subjects affected / exposed	9 / 88 (10.23%)	17 / 176 (9.66%)	23 / 177 (12.99%)
occurrences (all)	9	18	29
Bone pain			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Bursitis			
subjects affected / exposed	0 / 88 (0.00%)	3 / 176 (1.70%)	3 / 177 (1.69%)
occurrences (all)	0	6	3
Chest wall haematoma			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Chondrocalcinosis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Chondrocalcinosis pyrophosphate			
subjects affected / exposed	0 / 88 (0.00%)	3 / 176 (1.70%)	0 / 177 (0.00%)
occurrences (all)	0	5	0
Enthesopathy			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Exostosis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Flank pain			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	3 / 177 (1.69%)
occurrences (all)	0	0	5
Foot deformity			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	2 / 177 (1.13%)
occurrences (all)	1	1	3

Fracture pain			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Gouty tophus			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Groin pain			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	4 / 177 (2.26%)
occurrences (all)	1	0	4
Haemarthrosis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	3 / 177 (1.69%)
occurrences (all)	0	1	3
Intervertebral disc degeneration			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	1 / 177 (0.56%)
occurrences (all)	0	2	1
Intervertebral disc protrusion			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Intervertebral disc space narrowing			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Joint swelling			
subjects affected / exposed	2 / 88 (2.27%)	0 / 176 (0.00%)	5 / 177 (2.82%)
occurrences (all)	2	0	7
Knee deformity			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Limb discomfort			
subjects affected / exposed	2 / 88 (2.27%)	4 / 176 (2.27%)	1 / 177 (0.56%)
occurrences (all)	2	4	1
Lumbar spinal stenosis			
subjects affected / exposed	0 / 88 (0.00%)	3 / 176 (1.70%)	2 / 177 (1.13%)
occurrences (all)	0	5	2
Metatarsalgia			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0

Muscle atrophy			
subjects affected / exposed	2 / 88 (2.27%)	2 / 176 (1.14%)	5 / 177 (2.82%)
occurrences (all)	2	3	5
Muscle contracture			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Muscle spasms			
subjects affected / exposed	10 / 88 (11.36%)	15 / 176 (8.52%)	14 / 177 (7.91%)
occurrences (all)	13	15	19
Muscle twitching			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Muscular weakness			
subjects affected / exposed	2 / 88 (2.27%)	5 / 176 (2.84%)	12 / 177 (6.78%)
occurrences (all)	2	8	12
Musculoskeletal chest pain			
subjects affected / exposed	1 / 88 (1.14%)	3 / 176 (1.70%)	3 / 177 (1.69%)
occurrences (all)	1	3	3
Musculoskeletal discomfort			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	4 / 177 (2.26%)
occurrences (all)	1	1	5
Musculoskeletal pain			
subjects affected / exposed	3 / 88 (3.41%)	13 / 176 (7.39%)	11 / 177 (6.21%)
occurrences (all)	4	17	12
Musculoskeletal stiffness			
subjects affected / exposed	2 / 88 (2.27%)	3 / 176 (1.70%)	1 / 177 (0.56%)
occurrences (all)	2	3	1
Myalgia			
subjects affected / exposed	5 / 88 (5.68%)	5 / 176 (2.84%)	2 / 177 (1.13%)
occurrences (all)	7	5	2
Neck pain			
subjects affected / exposed	4 / 88 (4.55%)	3 / 176 (1.70%)	5 / 177 (2.82%)
occurrences (all)	4	3	5
Osteoarthritis			
subjects affected / exposed	2 / 88 (2.27%)	9 / 176 (5.11%)	6 / 177 (3.39%)
occurrences (all)	2	10	7

Osteopenia			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Osteoporosis			
subjects affected / exposed	2 / 88 (2.27%)	1 / 176 (0.57%)	3 / 177 (1.69%)
occurrences (all)	2	1	3
Pain in extremity			
subjects affected / exposed	6 / 88 (6.82%)	27 / 176 (15.34%)	20 / 177 (11.30%)
occurrences (all)	7	32	25
Pain in jaw			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Plantar fasciitis			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	0 / 177 (0.00%)
occurrences (all)	0	2	0
Polymyalgia rheumatica			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Psoriatic arthropathy			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Rotator cuff syndrome			
subjects affected / exposed	0 / 88 (0.00%)	5 / 176 (2.84%)	0 / 177 (0.00%)
occurrences (all)	0	7	0
Spinal column stenosis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	2	0
Spinal osteoarthritis			
subjects affected / exposed	0 / 88 (0.00%)	3 / 176 (1.70%)	2 / 177 (1.13%)
occurrences (all)	0	3	2
Spondylolisthesis			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	1 / 177 (0.56%)
occurrences (all)	0	3	1
Synovial cyst			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	2	1

Tendonitis			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	4 / 177 (2.26%)
occurrences (all)	0	2	5
Tenosynovitis			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Trigger finger			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	1	1	0
Infections and infestations			
Acute sinusitis			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	2 / 177 (1.13%)
occurrences (all)	0	3	3
Arthritis bacterial			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Bacteraemia			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Bacterial infection			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Bacterial abdominal infection			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Body tinea			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Bronchiolitis			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Bronchitis			
subjects affected / exposed	7 / 88 (7.95%)	21 / 176 (11.93%)	19 / 177 (10.73%)
occurrences (all)	8	24	20
Candida infection			

subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	0 / 177 (0.00%)
occurrences (all)	0	2	0
Candiduria			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Cellulitis			
subjects affected / exposed	6 / 88 (6.82%)	6 / 176 (3.41%)	10 / 177 (5.65%)
occurrences (all)	6	6	11
Chronic sinusitis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Conjunctivitis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	2 / 177 (1.13%)
occurrences (all)	0	1	2
Cystitis			
subjects affected / exposed	2 / 88 (2.27%)	5 / 176 (2.84%)	0 / 177 (0.00%)
occurrences (all)	2	5	0
Device related infection			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	1	1	1
Diverticulitis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Ear infection			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	1 / 177 (0.56%)
occurrences (all)	0	2	1
Endocarditis			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Enteritis infectious			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Enterococcal bacteraemia			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Erysipelas			

subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	2 / 177 (1.13%)
occurrences (all)	0	1	2
Escherichia urinary tract infection			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	0 / 177 (0.00%)
occurrences (all)	0	2	0
Eye infection			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	1 / 177 (0.56%)
occurrences (all)	0	2	1
Folliculitis			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Fungal infection			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Fungal skin infection			
subjects affected / exposed	2 / 88 (2.27%)	0 / 176 (0.00%)	2 / 177 (1.13%)
occurrences (all)	2	0	2
Gas gangrene			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Gastritis viral			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Gastroenteritis			
subjects affected / exposed	1 / 88 (1.14%)	5 / 176 (2.84%)	3 / 177 (1.69%)
occurrences (all)	1	5	4
Gastroenteritis viral			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Gastrointestinal infection			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	3 / 177 (1.69%)
occurrences (all)	0	0	3
Gastrointestinal viral infection			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Genitourinary tract infection			

subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	3 / 177 (1.69%)
occurrences (all)	1	0	5
Helicobacter gastritis			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Herpes zoster			
subjects affected / exposed	0 / 88 (0.00%)	6 / 176 (3.41%)	6 / 177 (3.39%)
occurrences (all)	0	9	7
Hordeolum			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	1 / 177 (0.56%)
occurrences (all)	0	2	1
Impetigo			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Infected cyst			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Infected dermal cyst			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Infected skin ulcer			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Influenza			
subjects affected / exposed	4 / 88 (4.55%)	7 / 176 (3.98%)	6 / 177 (3.39%)
occurrences (all)	5	8	6
Kidney infection			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Labyrinthitis			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	2 / 177 (1.13%)
occurrences (all)	0	0	2
Localised infection			
subjects affected / exposed	2 / 88 (2.27%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	2	0	0
Lower respiratory tract infection			

subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	3 / 177 (1.69%)
occurrences (all)	0	0	4
Lung infection			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	2	1	0
Molluscum contagiosum			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Nasopharyngitis			
subjects affected / exposed	7 / 88 (7.95%)	14 / 176 (7.95%)	17 / 177 (9.60%)
occurrences (all)	9	17	23
Oesophageal candidiasis			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Onychomycosis			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	2 / 177 (1.13%)
occurrences (all)	0	0	2
Oral candidiasis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Parotitis			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Periodontitis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Periorbital cellulitis			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Pharyngitis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Pneumonia			
subjects affected / exposed	4 / 88 (4.55%)	12 / 176 (6.82%)	7 / 177 (3.95%)
occurrences (all)	7	15	8
Pneumonia bacterial			

subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Pneumonia viral			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Post procedural infection			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	0 / 177 (0.00%)
occurrences (all)	0	2	0
Pulpitis dental			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Pyelonephritis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Pyuria			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Respiratory syncytial virus infection			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Respiratory tract infection			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	2 / 177 (1.13%)
occurrences (all)	1	1	2
Rhinitis			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	1 / 177 (0.56%)
occurrences (all)	0	2	1
Sepsis			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	1	1	1
Septic shock			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Sinusitis			
subjects affected / exposed	4 / 88 (4.55%)	10 / 176 (5.68%)	1 / 177 (0.56%)
occurrences (all)	4	12	1
Skin infection			

subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	0 / 177 (0.00%)
occurrences (all)	0	2	0
Staphylococcal sepsis			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Tooth abscess			
subjects affected / exposed	2 / 88 (2.27%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	3	1	1
Tooth infection			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	0	1	1
Tracheitis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Tracheobronchitis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	2	0
Upper respiratory tract infection			
subjects affected / exposed	7 / 88 (7.95%)	17 / 176 (9.66%)	16 / 177 (9.04%)
occurrences (all)	7	19	18
Urinary tract infection			
subjects affected / exposed	7 / 88 (7.95%)	15 / 176 (8.52%)	25 / 177 (14.12%)
occurrences (all)	10	18	33
Varicella zoster virus infection			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Viral infection			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	0 / 177 (0.00%)
occurrences (all)	0	2	0
Viral upper respiratory tract infection			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	1	1	1
Wound infection			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	0 / 177 (0.00%)
occurrences (all)	0	2	0
Gingivitis			

subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	1	2	1
Metabolism and nutrition disorders			
Adult failure to thrive			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Cachexia			
subjects affected / exposed	3 / 88 (3.41%)	1 / 176 (0.57%)	3 / 177 (1.69%)
occurrences (all)	3	2	3
Decreased appetite			
subjects affected / exposed	8 / 88 (9.09%)	14 / 176 (7.95%)	25 / 177 (14.12%)
occurrences (all)	9	15	25
Dehydration			
subjects affected / exposed	3 / 88 (3.41%)	4 / 176 (2.27%)	4 / 177 (2.26%)
occurrences (all)	3	4	4
Diabetes mellitus			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	5 / 177 (2.82%)
occurrences (all)	1	1	5
Diabetes mellitus inadequate control			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	2 / 177 (1.13%)
occurrences (all)	0	0	2
Fluid overload			
subjects affected / exposed	11 / 88 (12.50%)	18 / 176 (10.23%)	27 / 177 (15.25%)
occurrences (all)	12	31	44
Fluid retention			
subjects affected / exposed	3 / 88 (3.41%)	5 / 176 (2.84%)	15 / 177 (8.47%)
occurrences (all)	5	7	18
Gout			
subjects affected / exposed	10 / 88 (11.36%)	17 / 176 (9.66%)	29 / 177 (16.38%)
occurrences (all)	10	22	34
Hyperammonaemia			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Hypercalcaemia			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	2 / 177 (1.13%)
occurrences (all)	0	0	2

Hyperglycaemia			
subjects affected / exposed	1 / 88 (1.14%)	2 / 176 (1.14%)	3 / 177 (1.69%)
occurrences (all)	1	2	3
Hyperkalaemia			
subjects affected / exposed	1 / 88 (1.14%)	8 / 176 (4.55%)	10 / 177 (5.65%)
occurrences (all)	1	10	10
Hyperlactacidaemia			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Hyperlipidaemia			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Hyperuricaemia			
subjects affected / exposed	3 / 88 (3.41%)	9 / 176 (5.11%)	7 / 177 (3.95%)
occurrences (all)	3	10	7
Hypervolaemia			
subjects affected / exposed	1 / 88 (1.14%)	2 / 176 (1.14%)	0 / 177 (0.00%)
occurrences (all)	1	3	0
Hypoalbuminaemia			
subjects affected / exposed	2 / 88 (2.27%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	2	1	1
Hypocalcaemia			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Hypochloraemia			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	0 / 177 (0.00%)
occurrences (all)	1	0	0
Hypoglycaemia			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	2 / 177 (1.13%)
occurrences (all)	0	1	3
Hypokalaemia			
subjects affected / exposed	8 / 88 (9.09%)	14 / 176 (7.95%)	19 / 177 (10.73%)
occurrences (all)	8	15	28
Hypomagnesaemia			
subjects affected / exposed	1 / 88 (1.14%)	1 / 176 (0.57%)	1 / 177 (0.56%)
occurrences (all)	1	1	1

Hyponatraemia			
subjects affected / exposed	2 / 88 (2.27%)	8 / 176 (4.55%)	10 / 177 (5.65%)
occurrences (all)	3	8	12
Hypoproteinaemia			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	1	0	1
Hypovolaemia			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	1	0	1
Iron deficiency			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	2 / 177 (1.13%)
occurrences (all)	0	1	2
Malnutrition			
subjects affected / exposed	0 / 88 (0.00%)	2 / 176 (1.14%)	3 / 177 (1.69%)
occurrences (all)	0	2	3
Metabolic acidosis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	3 / 177 (1.69%)
occurrences (all)	0	1	3
Metabolic alkalosis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Metabolic disorder			
subjects affected / exposed	0 / 88 (0.00%)	1 / 176 (0.57%)	0 / 177 (0.00%)
occurrences (all)	0	1	0
Protein deficiency			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	1
Type 2 diabetes mellitus			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	2 / 177 (1.13%)
occurrences (all)	1	0	2
Vitamin B12 deficiency			
subjects affected / exposed	0 / 88 (0.00%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	0	0	4
Vitamin D deficiency			
subjects affected / exposed	1 / 88 (1.14%)	0 / 176 (0.00%)	1 / 177 (0.56%)
occurrences (all)	1	0	1

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
16 April 2014	Amended the week 2 follow-up to allow for flexibility.Expanded 30 month vital status determination to include transplant status.
26 February 2015	Added clarification for Hepatitis and HIV exclusion.
24 May 2016	Incorporated the discontinuation of enrollment of subjects with wild-type genotype in order to increase the numbers of subjects with variant genotype. Redefined the baseline groupings for New York Heart Association (NYHA) functional classification that will be used for efficacy analyses, grouping subjects with NYHA Class I and II together to be compared against NYHA Class III.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported